Muscular Dystrophy Society of Ireland GLC (Muscular Dystrophy Ireland)
Lobbying activity
The following activities occurred for this specific Subject Matter Area.
Letter (1)
Asking the Minister for Health to advise on the date of the HSE Drugs Group meeting re reimbursement of Givinostat (Duvyzat®) and continue to support the progression of the application through the final stages of reimbursement in a timely manner.
Also requesting that her department supports the timely approval of a full-time Clinical Nurse Manager Grade 2 position within CHI to ensure the treatment can be safely and effectively integrated into the care pathway without further delaying access.
Letter (1)
Requesting that the HSE consider the eligibility criteria adopted by UK National Institute for Health and Care Excellence (NICE) when determining access to Givinostat in Ireland. NICE includes boys with DMD who can walk, as well as those who can stand with or without support. Adopting a similar approach would help ensure fairness and avoid boys in the Republic being disadvantaged compared to their peers in Northern Ireland.
Designated public officials lobbied
The following DPOs were lobbied during this return period on this specific Subject Matter Area. These DPOs were involved in at least one of the Lobbying Activities listed above, but not necessarily all of them. As returns are specific to a Subject Matter Area the above Lobbying Activities may be associated with multiple returns.